Corpus
Pmc
Racine
Corpus
Checkpoint
Pmc
Racine
Pmc
Exploration
Accueil
Racine
Racine

Serveur d'exploration MERS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity

Identifieur interne : 000C02 ( Pmc/Corpus ); précédent : 000C01; suivant : 000C03

Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity

Auteurs : Jae-Hoon Ko ; Marcel A. Müller ; Hyeri Seok ; Ga Eun Park ; Ji Yeon Lee ; Sun Young Cho ; Young Eun Ha ; Jin Yang Baek ; So Hyun Kim ; Ji-Man Kang ; Yae-Jean Kim ; Ik Joon Jo ; Chi Ryang Chung ; Myong-Joon Hahn ; Christian Drosten ; Cheol-In Kang ; Doo Ryeon Chung ; Jae-Hoon Song ; Eun-Suk Kang ; Kyong Ran Peck

Source :

RBID : PMC:7127792

Abstract

We evaluated serologic response of 42 Middle East respiratory syndrome coronavirus (MERS-CoV)-infected patients according to 4 severity groups: asymptomatic infection (Group 0), symptomatic infection without pneumonia (Group 1), pneumonia without respiratory failure (Group 2), and pneumonia progressing to respiratory failure (Group 3). None of the Group 0 patients showed seroconversion, while the seroconversion rate gradually increased with increasing disease severity (0.0%, 60.0%, 93.8%, and 100% in Group 0, 1, 2, 3, respectively; P = 0.001). Group 3 patients showed delayed increment of antibody titers during the fourth week, while Group 2 patients showed robust increment of antibody titer during the third week. Among patients having pneumonia, 75% of deceased patients did not show seroconversion by the third week, while 100% of the survived patients were seroconverted (P = 0.003).


Url:
DOI: 10.1016/j.diagmicrobio.2017.07.006
PubMed: 28821364
PubMed Central: 7127792

Links to Exploration step

PMC:7127792

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity</title>
<author>
<name sortKey="Ko, Jae Hoon" sort="Ko, Jae Hoon" uniqKey="Ko J" first="Jae-Hoon" last="Ko">Jae-Hoon Ko</name>
<affiliation>
<nlm:aff id="af0005">Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Muller, Marcel A" sort="Muller, Marcel A" uniqKey="Muller M" first="Marcel A." last="Müller">Marcel A. Müller</name>
<affiliation>
<nlm:aff id="af0010">Institute of Virology, Charité - Universitätsmedizin Berlin, Berlin, Germany</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="af0015">German Centre for Infection Research, Germany</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Seok, Hyeri" sort="Seok, Hyeri" uniqKey="Seok H" first="Hyeri" last="Seok">Hyeri Seok</name>
<affiliation>
<nlm:aff id="af0005">Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Park, Ga Eun" sort="Park, Ga Eun" uniqKey="Park G" first="Ga Eun" last="Park">Ga Eun Park</name>
<affiliation>
<nlm:aff id="af0005">Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Lee, Ji Yeon" sort="Lee, Ji Yeon" uniqKey="Lee J" first="Ji Yeon" last="Lee">Ji Yeon Lee</name>
<affiliation>
<nlm:aff id="af0005">Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Cho, Sun Young" sort="Cho, Sun Young" uniqKey="Cho S" first="Sun Young" last="Cho">Sun Young Cho</name>
<affiliation>
<nlm:aff id="af0005">Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Ha, Young Eun" sort="Ha, Young Eun" uniqKey="Ha Y" first="Young Eun" last="Ha">Young Eun Ha</name>
<affiliation>
<nlm:aff id="af0005">Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Baek, Jin Yang" sort="Baek, Jin Yang" uniqKey="Baek J" first="Jin Yang" last="Baek">Jin Yang Baek</name>
<affiliation>
<nlm:aff id="af0020">Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Kim, So Hyun" sort="Kim, So Hyun" uniqKey="Kim S" first="So Hyun" last="Kim">So Hyun Kim</name>
<affiliation>
<nlm:aff id="af0020">Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Kang, Ji Man" sort="Kang, Ji Man" uniqKey="Kang J" first="Ji-Man" last="Kang">Ji-Man Kang</name>
<affiliation>
<nlm:aff id="af0025">Division of Infectious Diseases, Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Kim, Yae Jean" sort="Kim, Yae Jean" uniqKey="Kim Y" first="Yae-Jean" last="Kim">Yae-Jean Kim</name>
<affiliation>
<nlm:aff id="af0025">Division of Infectious Diseases, Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Jo, Ik Joon" sort="Jo, Ik Joon" uniqKey="Jo I" first="Ik Joon" last="Jo">Ik Joon Jo</name>
<affiliation>
<nlm:aff id="af0030">Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Chung, Chi Ryang" sort="Chung, Chi Ryang" uniqKey="Chung C" first="Chi Ryang" last="Chung">Chi Ryang Chung</name>
<affiliation>
<nlm:aff id="af0035">Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Hahn, Myong Joon" sort="Hahn, Myong Joon" uniqKey="Hahn M" first="Myong-Joon" last="Hahn">Myong-Joon Hahn</name>
<affiliation>
<nlm:aff id="af0040">Department of Molecular Cell Biology, Center for Molecular Medicine, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon 16419, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Drosten, Christian" sort="Drosten, Christian" uniqKey="Drosten C" first="Christian" last="Drosten">Christian Drosten</name>
<affiliation>
<nlm:aff id="af0010">Institute of Virology, Charité - Universitätsmedizin Berlin, Berlin, Germany</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="af0015">German Centre for Infection Research, Germany</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Kang, Cheol In" sort="Kang, Cheol In" uniqKey="Kang C" first="Cheol-In" last="Kang">Cheol-In Kang</name>
<affiliation>
<nlm:aff id="af0005">Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Chung, Doo Ryeon" sort="Chung, Doo Ryeon" uniqKey="Chung D" first="Doo Ryeon" last="Chung">Doo Ryeon Chung</name>
<affiliation>
<nlm:aff id="af0005">Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="af0020">Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Song, Jae Hoon" sort="Song, Jae Hoon" uniqKey="Song J" first="Jae-Hoon" last="Song">Jae-Hoon Song</name>
<affiliation>
<nlm:aff id="af0005">Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="af0020">Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Kang, Eun Suk" sort="Kang, Eun Suk" uniqKey="Kang E" first="Eun-Suk" last="Kang">Eun-Suk Kang</name>
<affiliation>
<nlm:aff id="af0045">Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Peck, Kyong Ran" sort="Peck, Kyong Ran" uniqKey="Peck K" first="Kyong Ran" last="Peck">Kyong Ran Peck</name>
<affiliation>
<nlm:aff id="af0005">Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea</nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmid">28821364</idno>
<idno type="pmc">7127792</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127792</idno>
<idno type="RBID">PMC:7127792</idno>
<idno type="doi">10.1016/j.diagmicrobio.2017.07.006</idno>
<date when="2017">2017</date>
<idno type="wicri:Area/Pmc/Corpus">000C02</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000C02</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity</title>
<author>
<name sortKey="Ko, Jae Hoon" sort="Ko, Jae Hoon" uniqKey="Ko J" first="Jae-Hoon" last="Ko">Jae-Hoon Ko</name>
<affiliation>
<nlm:aff id="af0005">Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Muller, Marcel A" sort="Muller, Marcel A" uniqKey="Muller M" first="Marcel A." last="Müller">Marcel A. Müller</name>
<affiliation>
<nlm:aff id="af0010">Institute of Virology, Charité - Universitätsmedizin Berlin, Berlin, Germany</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="af0015">German Centre for Infection Research, Germany</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Seok, Hyeri" sort="Seok, Hyeri" uniqKey="Seok H" first="Hyeri" last="Seok">Hyeri Seok</name>
<affiliation>
<nlm:aff id="af0005">Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Park, Ga Eun" sort="Park, Ga Eun" uniqKey="Park G" first="Ga Eun" last="Park">Ga Eun Park</name>
<affiliation>
<nlm:aff id="af0005">Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Lee, Ji Yeon" sort="Lee, Ji Yeon" uniqKey="Lee J" first="Ji Yeon" last="Lee">Ji Yeon Lee</name>
<affiliation>
<nlm:aff id="af0005">Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Cho, Sun Young" sort="Cho, Sun Young" uniqKey="Cho S" first="Sun Young" last="Cho">Sun Young Cho</name>
<affiliation>
<nlm:aff id="af0005">Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Ha, Young Eun" sort="Ha, Young Eun" uniqKey="Ha Y" first="Young Eun" last="Ha">Young Eun Ha</name>
<affiliation>
<nlm:aff id="af0005">Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Baek, Jin Yang" sort="Baek, Jin Yang" uniqKey="Baek J" first="Jin Yang" last="Baek">Jin Yang Baek</name>
<affiliation>
<nlm:aff id="af0020">Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Kim, So Hyun" sort="Kim, So Hyun" uniqKey="Kim S" first="So Hyun" last="Kim">So Hyun Kim</name>
<affiliation>
<nlm:aff id="af0020">Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Kang, Ji Man" sort="Kang, Ji Man" uniqKey="Kang J" first="Ji-Man" last="Kang">Ji-Man Kang</name>
<affiliation>
<nlm:aff id="af0025">Division of Infectious Diseases, Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Kim, Yae Jean" sort="Kim, Yae Jean" uniqKey="Kim Y" first="Yae-Jean" last="Kim">Yae-Jean Kim</name>
<affiliation>
<nlm:aff id="af0025">Division of Infectious Diseases, Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Jo, Ik Joon" sort="Jo, Ik Joon" uniqKey="Jo I" first="Ik Joon" last="Jo">Ik Joon Jo</name>
<affiliation>
<nlm:aff id="af0030">Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Chung, Chi Ryang" sort="Chung, Chi Ryang" uniqKey="Chung C" first="Chi Ryang" last="Chung">Chi Ryang Chung</name>
<affiliation>
<nlm:aff id="af0035">Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Hahn, Myong Joon" sort="Hahn, Myong Joon" uniqKey="Hahn M" first="Myong-Joon" last="Hahn">Myong-Joon Hahn</name>
<affiliation>
<nlm:aff id="af0040">Department of Molecular Cell Biology, Center for Molecular Medicine, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon 16419, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Drosten, Christian" sort="Drosten, Christian" uniqKey="Drosten C" first="Christian" last="Drosten">Christian Drosten</name>
<affiliation>
<nlm:aff id="af0010">Institute of Virology, Charité - Universitätsmedizin Berlin, Berlin, Germany</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="af0015">German Centre for Infection Research, Germany</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Kang, Cheol In" sort="Kang, Cheol In" uniqKey="Kang C" first="Cheol-In" last="Kang">Cheol-In Kang</name>
<affiliation>
<nlm:aff id="af0005">Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Chung, Doo Ryeon" sort="Chung, Doo Ryeon" uniqKey="Chung D" first="Doo Ryeon" last="Chung">Doo Ryeon Chung</name>
<affiliation>
<nlm:aff id="af0005">Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="af0020">Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Song, Jae Hoon" sort="Song, Jae Hoon" uniqKey="Song J" first="Jae-Hoon" last="Song">Jae-Hoon Song</name>
<affiliation>
<nlm:aff id="af0005">Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea</nlm:aff>
</affiliation>
<affiliation>
<nlm:aff id="af0020">Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Kang, Eun Suk" sort="Kang, Eun Suk" uniqKey="Kang E" first="Eun-Suk" last="Kang">Eun-Suk Kang</name>
<affiliation>
<nlm:aff id="af0045">Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Peck, Kyong Ran" sort="Peck, Kyong Ran" uniqKey="Peck K" first="Kyong Ran" last="Peck">Kyong Ran Peck</name>
<affiliation>
<nlm:aff id="af0005">Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea</nlm:aff>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Diagnostic Microbiology and Infectious Disease</title>
<idno type="ISSN">0732-8893</idno>
<idno type="eISSN">1879-0070</idno>
<imprint>
<date when="2017">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p>We evaluated serologic response of 42 Middle East respiratory syndrome coronavirus (MERS-CoV)-infected patients according to 4 severity groups: asymptomatic infection (Group 0), symptomatic infection without pneumonia (Group 1), pneumonia without respiratory failure (Group 2), and pneumonia progressing to respiratory failure (Group 3). None of the Group 0 patients showed seroconversion, while the seroconversion rate gradually increased with increasing disease severity (0.0%, 60.0%, 93.8%, and 100% in Group 0, 1, 2, 3, respectively;
<italic>P</italic>
= 0.001). Group 3 patients showed delayed increment of antibody titers during the fourth week, while Group 2 patients showed robust increment of antibody titer during the third week. Among patients having pneumonia, 75% of deceased patients did not show seroconversion by the third week, while 100% of the survived patients were seroconverted (
<italic>P</italic>
= 0.003).</p>
</div>
</front>
<back>
<div1 type="bibliography">
<listBibl>
<biblStruct>
<analytic>
<author>
<name sortKey="Breakwell, L" uniqKey="Breakwell L">L. Breakwell</name>
</author>
<author>
<name sortKey="Pringle, K" uniqKey="Pringle K">K. Pringle</name>
</author>
<author>
<name sortKey="Chea, N" uniqKey="Chea N">N. Chea</name>
</author>
<author>
<name sortKey="Allen, D" uniqKey="Allen D">D. Allen</name>
</author>
<author>
<name sortKey="Allen, S" uniqKey="Allen S">S. Allen</name>
</author>
<author>
<name sortKey="Richards, S" uniqKey="Richards S">S. Richards</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Buchholz, U" uniqKey="Buchholz U">U. Buchholz</name>
</author>
<author>
<name sortKey="Muller, M A" uniqKey="Muller M">M.A. Muller</name>
</author>
<author>
<name sortKey="Nitsche, A" uniqKey="Nitsche A">A. Nitsche</name>
</author>
<author>
<name sortKey="Sanewski, A" uniqKey="Sanewski A">A. Sanewski</name>
</author>
<author>
<name sortKey="Wevering, N" uniqKey="Wevering N">N. Wevering</name>
</author>
<author>
<name sortKey="Bauer Balci, T" uniqKey="Bauer Balci T">T. Bauer-Balci</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Cho, S Y" uniqKey="Cho S">S.Y. Cho</name>
</author>
<author>
<name sortKey="Kang, J M" uniqKey="Kang J">J.M. Kang</name>
</author>
<author>
<name sortKey="Ha, Y E" uniqKey="Ha Y">Y.E. Ha</name>
</author>
<author>
<name sortKey="Park, G E" uniqKey="Park G">G.E. Park</name>
</author>
<author>
<name sortKey="Lee, J Y" uniqKey="Lee J">J.Y. Lee</name>
</author>
<author>
<name sortKey="Ko, J H" uniqKey="Ko J">J.H. Ko</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Choe, P G" uniqKey="Choe P">P.G. Choe</name>
</author>
<author>
<name sortKey="Perera, R" uniqKey="Perera R">R. Perera</name>
</author>
<author>
<name sortKey="Park, W B" uniqKey="Park W">W.B. Park</name>
</author>
<author>
<name sortKey="Song, K H" uniqKey="Song K">K.H. Song</name>
</author>
<author>
<name sortKey="Bang, J H" uniqKey="Bang J">J.H. Bang</name>
</author>
<author>
<name sortKey="Kim, E S" uniqKey="Kim E">E.S. Kim</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Choi, W S" uniqKey="Choi W">W.S. Choi</name>
</author>
<author>
<name sortKey="Kang, C I" uniqKey="Kang C">C.I. Kang</name>
</author>
<author>
<name sortKey="Kim, Y" uniqKey="Kim Y">Y. Kim</name>
</author>
<author>
<name sortKey="Choi, J P" uniqKey="Choi J">J.P. Choi</name>
</author>
<author>
<name sortKey="Joh, J S" uniqKey="Joh J">J.S. Joh</name>
</author>
<author>
<name sortKey="Shin, H S" uniqKey="Shin H">H.S. Shin</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Corman, V M" uniqKey="Corman V">V.M. Corman</name>
</author>
<author>
<name sortKey="Albarrak, A M" uniqKey="Albarrak A">A.M. Albarrak</name>
</author>
<author>
<name sortKey="Omrani, A S" uniqKey="Omrani A">A.S. Omrani</name>
</author>
<author>
<name sortKey="Albarrak, M M" uniqKey="Albarrak M">M.M. Albarrak</name>
</author>
<author>
<name sortKey="Farah, M E" uniqKey="Farah M">M.E. Farah</name>
</author>
<author>
<name sortKey="Almasri, M" uniqKey="Almasri M">M. Almasri</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Corman, V M" uniqKey="Corman V">V.M. Corman</name>
</author>
<author>
<name sortKey="Eckerle, I" uniqKey="Eckerle I">I. Eckerle</name>
</author>
<author>
<name sortKey="Bleicker, T" uniqKey="Bleicker T">T. Bleicker</name>
</author>
<author>
<name sortKey="Zaki, A" uniqKey="Zaki A">A. Zaki</name>
</author>
<author>
<name sortKey="Landt, O" uniqKey="Landt O">O. Landt</name>
</author>
<author>
<name sortKey="Eschbach Bludau, M" uniqKey="Eschbach Bludau M">M. Eschbach-Bludau</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Corman, V M" uniqKey="Corman V">V.M. Corman</name>
</author>
<author>
<name sortKey="Muller, M A" uniqKey="Muller M">M.A. Muller</name>
</author>
<author>
<name sortKey="Costabel, U" uniqKey="Costabel U">U. Costabel</name>
</author>
<author>
<name sortKey="Timm, J" uniqKey="Timm J">J. Timm</name>
</author>
<author>
<name sortKey="Binger, T" uniqKey="Binger T">T. Binger</name>
</author>
<author>
<name sortKey="Meyer, B" uniqKey="Meyer B">B. Meyer</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Kim, Y" uniqKey="Kim Y">Y. Kim</name>
</author>
<author>
<name sortKey="Lee, S" uniqKey="Lee S">S. Lee</name>
</author>
<author>
<name sortKey="Chu, C" uniqKey="Chu C">C. Chu</name>
</author>
<author>
<name sortKey="Choe, S" uniqKey="Choe S">S. Choe</name>
</author>
<author>
<name sortKey="Hong, S" uniqKey="Hong S">S. Hong</name>
</author>
<author>
<name sortKey="Shin, Y" uniqKey="Shin Y">Y. Shin</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Ko, J H" uniqKey="Ko J">J.H. Ko</name>
</author>
<author>
<name sortKey="Lee, J Y" uniqKey="Lee J">J.Y. Lee</name>
</author>
<author>
<name sortKey="Baek, J Y" uniqKey="Baek J">J.Y. Baek</name>
</author>
<author>
<name sortKey="Seok, H" uniqKey="Seok H">H. Seok</name>
</author>
<author>
<name sortKey="Park, G E" uniqKey="Park G">G.E. Park</name>
</author>
<author>
<name sortKey="Lee, J Y" uniqKey="Lee J">J.Y. Lee</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Ko, J H" uniqKey="Ko J">J.H. Ko</name>
</author>
<author>
<name sortKey="Muller, M A" uniqKey="Muller M">M.A. Müller</name>
</author>
<author>
<name sortKey="Seok, H" uniqKey="Seok H">H. Seok</name>
</author>
<author>
<name sortKey="Park, G E" uniqKey="Park G">G.E. Park</name>
</author>
<author>
<name sortKey="Lee, J Y" uniqKey="Lee J">J.Y. Lee</name>
</author>
<author>
<name sortKey="Cho, S Y" uniqKey="Cho S">S.Y. Cho</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Ko, J H" uniqKey="Ko J">J.H. Ko</name>
</author>
<author>
<name sortKey="Park, G E" uniqKey="Park G">G.E. Park</name>
</author>
<author>
<name sortKey="Lee, J Y" uniqKey="Lee J">J.Y. Lee</name>
</author>
<author>
<name sortKey="Lee, J Y" uniqKey="Lee J">J.Y. Lee</name>
</author>
<author>
<name sortKey="Cho, S Y" uniqKey="Cho S">S.Y. Cho</name>
</author>
<author>
<name sortKey="Ha, Y E" uniqKey="Ha Y">Y.E. Ha</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Madani, T A" uniqKey="Madani T">T.A. Madani</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Meyer, B" uniqKey="Meyer B">B. Meyer</name>
</author>
<author>
<name sortKey="Muller, M A" uniqKey="Muller M">M.A. Muller</name>
</author>
<author>
<name sortKey="Corman, V M" uniqKey="Corman V">V.M. Corman</name>
</author>
<author>
<name sortKey="Reusken, C B" uniqKey="Reusken C">C.B. Reusken</name>
</author>
<author>
<name sortKey="Ritz, D" uniqKey="Ritz D">D. Ritz</name>
</author>
<author>
<name sortKey="Godeke, G J" uniqKey="Godeke G">G.J. Godeke</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Min, C K" uniqKey="Min C">C.K. Min</name>
</author>
<author>
<name sortKey="Cheon, S" uniqKey="Cheon S">S. Cheon</name>
</author>
<author>
<name sortKey="Ha, N Y" uniqKey="Ha N">N.Y. Ha</name>
</author>
<author>
<name sortKey="Sohn, K M" uniqKey="Sohn K">K.M. Sohn</name>
</author>
<author>
<name sortKey="Kim, Y" uniqKey="Kim Y">Y. Kim</name>
</author>
<author>
<name sortKey="Aigerim, A" uniqKey="Aigerim A">A. Aigerim</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Muller, M A" uniqKey="Muller M">M.A. Muller</name>
</author>
<author>
<name sortKey="Corman, V M" uniqKey="Corman V">V.M. Corman</name>
</author>
<author>
<name sortKey="Jores, J" uniqKey="Jores J">J. Jores</name>
</author>
<author>
<name sortKey="Meyer, B" uniqKey="Meyer B">B. Meyer</name>
</author>
<author>
<name sortKey="Younan, M" uniqKey="Younan M">M. Younan</name>
</author>
<author>
<name sortKey="Liljander, A" uniqKey="Liljander A">A. Liljander</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Muller, M A" uniqKey="Muller M">M.A. Muller</name>
</author>
<author>
<name sortKey="Meyer, B" uniqKey="Meyer B">B. Meyer</name>
</author>
<author>
<name sortKey="Corman, V M" uniqKey="Corman V">V.M. Corman</name>
</author>
<author>
<name sortKey="Al Masri, M" uniqKey="Al Masri M">M. Al-Masri</name>
</author>
<author>
<name sortKey="Turkestani, A" uniqKey="Turkestani A">A. Turkestani</name>
</author>
<author>
<name sortKey="Ritz, D" uniqKey="Ritz D">D. Ritz</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Muth, D" uniqKey="Muth D">D. Muth</name>
</author>
<author>
<name sortKey="Corman, V M" uniqKey="Corman V">V.M. Corman</name>
</author>
<author>
<name sortKey="Meyer, B" uniqKey="Meyer B">B. Meyer</name>
</author>
<author>
<name sortKey="Assiri, A" uniqKey="Assiri A">A. Assiri</name>
</author>
<author>
<name sortKey="Al Masri, M" uniqKey="Al Masri M">M. Al-Masri</name>
</author>
<author>
<name sortKey="Farah, M" uniqKey="Farah M">M. Farah</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Park, G E" uniqKey="Park G">G.E. Park</name>
</author>
<author>
<name sortKey="Ko, J H" uniqKey="Ko J">J.H. Ko</name>
</author>
<author>
<name sortKey="Peck, K R" uniqKey="Peck K">K.R. Peck</name>
</author>
<author>
<name sortKey="Lee, J Y" uniqKey="Lee J">J.Y. Lee</name>
</author>
<author>
<name sortKey="Lee, J Y" uniqKey="Lee J">J.Y. Lee</name>
</author>
<author>
<name sortKey="Cho, S Y" uniqKey="Cho S">S.Y. Cho</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Park, W B" uniqKey="Park W">W.B. Park</name>
</author>
<author>
<name sortKey="Perera, R A" uniqKey="Perera R">R.A. Perera</name>
</author>
<author>
<name sortKey="Choe, P G" uniqKey="Choe P">P.G. Choe</name>
</author>
<author>
<name sortKey="Lau, E H" uniqKey="Lau E">E.H. Lau</name>
</author>
<author>
<name sortKey="Choi, S J" uniqKey="Choi S">S.J. Choi</name>
</author>
<author>
<name sortKey="Chun, J Y" uniqKey="Chun J">J.Y. Chun</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Payne, D C" uniqKey="Payne D">D.C. Payne</name>
</author>
<author>
<name sortKey="Iblan, I" uniqKey="Iblan I">I. Iblan</name>
</author>
<author>
<name sortKey="Rha, B" uniqKey="Rha B">B. Rha</name>
</author>
<author>
<name sortKey="Alqasrawi, S" uniqKey="Alqasrawi S">S. Alqasrawi</name>
</author>
<author>
<name sortKey="Haddadin, A" uniqKey="Haddadin A">A. Haddadin</name>
</author>
<author>
<name sortKey="Al Nsour, M" uniqKey="Al Nsour M">M. Al Nsour</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Raj, V S" uniqKey="Raj V">V.S. Raj</name>
</author>
<author>
<name sortKey="Mou, H" uniqKey="Mou H">H. Mou</name>
</author>
<author>
<name sortKey="Smits, S L" uniqKey="Smits S">S.L. Smits</name>
</author>
<author>
<name sortKey="Dekkers, D H" uniqKey="Dekkers D">D.H. Dekkers</name>
</author>
<author>
<name sortKey="Muller, M A" uniqKey="Muller M">M.A. Muller</name>
</author>
<author>
<name sortKey="Dijkman, R" uniqKey="Dijkman R">R. Dijkman</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="World Health Organization Who" uniqKey="World Health Organization Who">World Health Organization (WHO)</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Zaki, A M" uniqKey="Zaki A">A.M. Zaki</name>
</author>
<author>
<name sortKey="Van Boheemen, S" uniqKey="Van Boheemen S">S. van Boheemen</name>
</author>
<author>
<name sortKey="Bestebroer, T M" uniqKey="Bestebroer T">T.M. Bestebroer</name>
</author>
<author>
<name sortKey="Osterhaus, A D" uniqKey="Osterhaus A">A.D. Osterhaus</name>
</author>
<author>
<name sortKey="Fouchier, R A" uniqKey="Fouchier R">R.A. Fouchier</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Zumla, A" uniqKey="Zumla A">A. Zumla</name>
</author>
<author>
<name sortKey="Hui, D S" uniqKey="Hui D">D.S. Hui</name>
</author>
<author>
<name sortKey="Perlman, S" uniqKey="Perlman S">S. Perlman</name>
</author>
</analytic>
</biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<pmc article-type="research-article">
<pmc-dir>properties open_access</pmc-dir>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Diagn Microbiol Infect Dis</journal-id>
<journal-id journal-id-type="iso-abbrev">Diagn. Microbiol. Infect. Dis</journal-id>
<journal-title-group>
<journal-title>Diagnostic Microbiology and Infectious Disease</journal-title>
</journal-title-group>
<issn pub-type="ppub">0732-8893</issn>
<issn pub-type="epub">1879-0070</issn>
<publisher>
<publisher-name>Elsevier Inc.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28821364</article-id>
<article-id pub-id-type="pmc">7127792</article-id>
<article-id pub-id-type="publisher-id">S0732-8893(17)30221-3</article-id>
<article-id pub-id-type="doi">10.1016/j.diagmicrobio.2017.07.006</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="au0005">
<name>
<surname>Ko</surname>
<given-names>Jae-Hoon</given-names>
</name>
<xref rid="af0005" ref-type="aff">a</xref>
<xref rid="fn0005" ref-type="fn">1</xref>
<xref rid="fn0010" ref-type="fn">2</xref>
</contrib>
<contrib contrib-type="author" id="au0010">
<name>
<surname>Müller</surname>
<given-names>Marcel A.</given-names>
</name>
<xref rid="af0010" ref-type="aff">b</xref>
<xref rid="af0015" ref-type="aff">c</xref>
<xref rid="fn0005" ref-type="fn">1</xref>
</contrib>
<contrib contrib-type="author" id="au0015">
<name>
<surname>Seok</surname>
<given-names>Hyeri</given-names>
</name>
<xref rid="af0005" ref-type="aff">a</xref>
</contrib>
<contrib contrib-type="author" id="au0020">
<name>
<surname>Park</surname>
<given-names>Ga Eun</given-names>
</name>
<xref rid="af0005" ref-type="aff">a</xref>
</contrib>
<contrib contrib-type="author" id="au0025">
<name>
<surname>Lee</surname>
<given-names>Ji Yeon</given-names>
</name>
<xref rid="af0005" ref-type="aff">a</xref>
</contrib>
<contrib contrib-type="author" id="au0030">
<name>
<surname>Cho</surname>
<given-names>Sun Young</given-names>
</name>
<xref rid="af0005" ref-type="aff">a</xref>
</contrib>
<contrib contrib-type="author" id="au0035">
<name>
<surname>Ha</surname>
<given-names>Young Eun</given-names>
</name>
<xref rid="af0005" ref-type="aff">a</xref>
</contrib>
<contrib contrib-type="author" id="au0040">
<name>
<surname>Baek</surname>
<given-names>Jin Yang</given-names>
</name>
<xref rid="af0020" ref-type="aff">d</xref>
</contrib>
<contrib contrib-type="author" id="au0045">
<name>
<surname>Kim</surname>
<given-names>So Hyun</given-names>
</name>
<xref rid="af0020" ref-type="aff">d</xref>
</contrib>
<contrib contrib-type="author" id="au0050">
<name>
<surname>Kang</surname>
<given-names>Ji-Man</given-names>
</name>
<xref rid="af0025" ref-type="aff">e</xref>
</contrib>
<contrib contrib-type="author" id="au0055">
<name>
<surname>Kim</surname>
<given-names>Yae-Jean</given-names>
</name>
<xref rid="af0025" ref-type="aff">e</xref>
</contrib>
<contrib contrib-type="author" id="au0060">
<name>
<surname>Jo</surname>
<given-names>Ik Joon</given-names>
</name>
<xref rid="af0030" ref-type="aff">f</xref>
</contrib>
<contrib contrib-type="author" id="au0065">
<name>
<surname>Chung</surname>
<given-names>Chi Ryang</given-names>
</name>
<xref rid="af0035" ref-type="aff">g</xref>
</contrib>
<contrib contrib-type="author" id="au0070">
<name>
<surname>Hahn</surname>
<given-names>Myong-Joon</given-names>
</name>
<xref rid="af0040" ref-type="aff">h</xref>
</contrib>
<contrib contrib-type="author" id="au0075">
<name>
<surname>Drosten</surname>
<given-names>Christian</given-names>
</name>
<xref rid="af0010" ref-type="aff">b</xref>
<xref rid="af0015" ref-type="aff">c</xref>
</contrib>
<contrib contrib-type="author" id="au0080">
<name>
<surname>Kang</surname>
<given-names>Cheol-In</given-names>
</name>
<xref rid="af0005" ref-type="aff">a</xref>
</contrib>
<contrib contrib-type="author" id="au0085">
<name>
<surname>Chung</surname>
<given-names>Doo Ryeon</given-names>
</name>
<xref rid="af0005" ref-type="aff">a</xref>
<xref rid="af0020" ref-type="aff">d</xref>
</contrib>
<contrib contrib-type="author" id="au0090">
<name>
<surname>Song</surname>
<given-names>Jae-Hoon</given-names>
</name>
<xref rid="af0005" ref-type="aff">a</xref>
<xref rid="af0020" ref-type="aff">d</xref>
</contrib>
<contrib contrib-type="author" id="au0095">
<name>
<surname>Kang</surname>
<given-names>Eun-Suk</given-names>
</name>
<email>eskang@skku.edu</email>
<xref rid="af0045" ref-type="aff">i</xref>
<xref rid="cr0005" ref-type="corresp">⁎</xref>
<xref rid="fn0015" ref-type="fn">3</xref>
</contrib>
<contrib contrib-type="author" id="au0100">
<name>
<surname>Peck</surname>
<given-names>Kyong Ran</given-names>
</name>
<email>krpeck@skku.edu</email>
<xref rid="af0005" ref-type="aff">a</xref>
<xref rid="cr0010" ref-type="corresp">⁎⁎</xref>
<xref rid="fn0015" ref-type="fn">3</xref>
</contrib>
</contrib-group>
<aff id="af0005">
<label>a</label>
Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea</aff>
<aff id="af0010">
<label>b</label>
Institute of Virology, Charité - Universitätsmedizin Berlin, Berlin, Germany</aff>
<aff id="af0015">
<label>c</label>
German Centre for Infection Research, Germany</aff>
<aff id="af0020">
<label>d</label>
Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, Republic of Korea</aff>
<aff id="af0025">
<label>e</label>
Division of Infectious Diseases, Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea</aff>
<aff id="af0030">
<label>f</label>
Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea</aff>
<aff id="af0035">
<label>g</label>
Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea</aff>
<aff id="af0040">
<label>h</label>
Department of Molecular Cell Biology, Center for Molecular Medicine, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon 16419, Republic of Korea</aff>
<aff id="af0045">
<label>i</label>
Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea</aff>
<author-notes>
<corresp id="cr0005">
<label>⁎</label>
Corresponding author. Tel.: +82-2-3410-2703; fax: +82-2-3410-2719.
<email>eskang@skku.edu</email>
</corresp>
<corresp id="cr0010">
<label>⁎⁎</label>
Corresponding author. Tel.: +82-2-3410-0329; fax: +82-2-3410-0064.
<email>krpeck@skku.edu</email>
</corresp>
<fn id="fn0005">
<label>1</label>
<p id="np0020">These authors contributed equally to this article as first authors.</p>
</fn>
<fn id="fn0010">
<label>2</label>
<p id="np0025">Present address: Division of Infectious Diseases, Department of Internal Medicine, Armed Forces Capital Hospital, Seongnam, Korea.</p>
</fn>
<fn id="fn0015">
<label>3</label>
<p id="np0030">These corresponding authors contributed equally to this article.</p>
</fn>
</author-notes>
<pub-date pub-type="pmc-release">
<day>14</day>
<month>7</month>
<year>2017</year>
</pub-date>
<pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="ppub">
<month>10</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>14</day>
<month>7</month>
<year>2017</year>
</pub-date>
<volume>89</volume>
<issue>2</issue>
<fpage>106</fpage>
<lpage>111</lpage>
<history>
<date date-type="received">
<day>28</day>
<month>4</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>5</day>
<month>7</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>7</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© 2017 Elsevier Inc. All rights reserved.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Elsevier Inc.</copyright-holder>
<license>
<license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p>
</license>
</permissions>
<abstract id="ab0005">
<p>We evaluated serologic response of 42 Middle East respiratory syndrome coronavirus (MERS-CoV)-infected patients according to 4 severity groups: asymptomatic infection (Group 0), symptomatic infection without pneumonia (Group 1), pneumonia without respiratory failure (Group 2), and pneumonia progressing to respiratory failure (Group 3). None of the Group 0 patients showed seroconversion, while the seroconversion rate gradually increased with increasing disease severity (0.0%, 60.0%, 93.8%, and 100% in Group 0, 1, 2, 3, respectively;
<italic>P</italic>
= 0.001). Group 3 patients showed delayed increment of antibody titers during the fourth week, while Group 2 patients showed robust increment of antibody titer during the third week. Among patients having pneumonia, 75% of deceased patients did not show seroconversion by the third week, while 100% of the survived patients were seroconverted (
<italic>P</italic>
= 0.003).</p>
</abstract>
<abstract abstract-type="author-highlights" id="ab0010">
<title>Highlights</title>
<p>
<list list-type="simple" id="l0005">
<list-item id="li0005">
<label>•</label>
<p id="p0005">Serologic responses of 42 MERS-CoV-infected patients were evaluated.</p>
</list-item>
<list-item id="li0010">
<label>•</label>
<p id="p0010">Patients were divided into 4 disease severity groups.</p>
</list-item>
<list-item id="li0015">
<label>•</label>
<p id="p0015">The seroconversion rate gradually increased with increasing disease severity.</p>
</list-item>
<list-item id="li0020">
<label>•</label>
<p id="p0020">Seventy-five percent of deceased patients did not show seroconversion by the third week.</p>
</list-item>
</list>
</p>
</abstract>
<kwd-group id="ks0005">
<title>Keywords</title>
<kwd>Middle East respiratory syndrome coronavirus</kwd>
<kwd>Prognosis</kwd>
<kwd>Antibody</kwd>
<kwd>Serologic response</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s0005">
<label>1</label>
<title>Introduction</title>
<p id="p0025">Since the first reported case of Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 (
<xref rid="bb0115" ref-type="bibr">Zaki et al., 2012</xref>
), small and large outbreaks have occurred, resulting in 1917 MERS-CoV infections and 677 related deaths to date (
<xref rid="bb0110" ref-type="bibr">WHO, 2017</xref>
). To understand this fatal respiratory viral infection, several serologic investigations have been conducted (
<xref rid="bb0030" ref-type="bibr">Corman et al., 2016</xref>
,
<xref rid="bb0070" ref-type="bibr">Min et al., 2016</xref>
,
<xref rid="bb0095" ref-type="bibr">Park et al., 2015</xref>
,
<xref rid="bb0100" ref-type="bibr">Payne et al., 2016</xref>
). However, practical analysis of serodiagnostic parameters for clinical usage was limited in previous studies, due to insufficient sample size or clinical information. We managed 45 MERS-CoV-infected patients, which is the largest number of patients as a single center during the 2015 Korean MERS outbreak (total 186 patients identified) (
<xref rid="bb0015" ref-type="bibr">Cho et al., 2016</xref>
,
<xref rid="bb0045" ref-type="bibr">Kim et al., 2016</xref>
,
<xref rid="bb0090" ref-type="bibr">Park et al., 2016</xref>
), and reported that MERS-CoV-infected patients experienced 4 distinct clinical courses, ranging from asymptomatic infection to severe pneumonia requiring mechanical ventilation (
<xref rid="bb0055" ref-type="bibr">Ko et al., 2016</xref>
). Based on these findings, we evaluated serologic response of 42 MERS-CoV-infected patients according to the disease severity to investigate potential role of serodiagnostic parameters as prognostic markers.</p>
</sec>
<sec id="s0010">
<label>2</label>
<title>Material and methods</title>
<sec id="s0015">
<label>2.1</label>
<title>Study population and samples</title>
<p id="p0030">Among 45 MERS-CoV-infected patients who were admitted to Samsung Medical Center, a 1950-bed tertiary care university hospital, during the 2015 Korean MERS outbreak (
<xref rid="bb0055" ref-type="bibr">Ko et al., 2016</xref>
), we obtained sera from 42 patients. MERS-CoV infections were confirmed on the basis of real-time reverse transcriptase polymerase chain reaction (rRT-PCR) assays targeting upstream of the E gene (upE) and the open-reading frame gene 1a (ORF1a) (
<xref rid="bb0035" ref-type="bibr">Corman et al., 2012a</xref>
,
<xref rid="bb0060" ref-type="bibr">Madani, 2014</xref>
). Epidemiologic investigation data and electronic medical records were reviewed to obtain exact exposure date, symptom onset, clinical course, and outcome data for the patients. One or 2 residual serum samples per week of illness were used for serologic testing during hospitalization periods. Follow-up serum samples obtained at outpatient clinics were also tested up to 6 months from symptom onset. The institutional review board of Samsung Medical Center approved the present study.</p>
</sec>
<sec id="s0020">
<label>2.2</label>
<title>Patient grouping according to the disease severity</title>
<p id="p0035">The clinical course of MERS-CoV-infected patients was assessed 6 weeks after symptom onset and patients were divided into 4 disease severity groups: asymptomatic infection (Group 0), symptomatic infection without pneumonia (Group 1), pneumonia without respiratory failure (Group 2), and pneumonia progressing to respiratory failure (Group 3) (
<xref rid="bb0055" ref-type="bibr">Ko et al., 2016</xref>
). For practical purposes, respiratory failure was defined as the need for mechanical ventilation. Only patients in Group 3 experienced fatal outcomes (5/13, 38.5%), and interval from symptom onset to death was 27 days in median (IQR 19–35.5). Proportion of underlying immunocompromising conditions including diabetes, solid cancer, or hematologic malignancies was not different between groups (
<xref rid="bb0055" ref-type="bibr">Ko et al., 2016</xref>
). The distinct clinical presentation of the 4 severity groups are presented in Supplementary Figs. 1 and 2, and Supplementary Table 1, in addition to the previous report (
<xref rid="bb0055" ref-type="bibr">Ko et al., 2016</xref>
).</p>
</sec>
<sec id="s0025">
<label>2.3</label>
<title>Definitions</title>
<p id="p0040">Seroconversion status was determined based on neutralization activity: if none of the serum samples from a MERS-CoV-infected patient, necessarily including sera obtained after the third week of illness, showed neutralization activity, the patient was considered to have negative seroconversion; if none of the serum samples obtained by the end of the third week of illness showed neutralization activity and no samples were available for neutralization tests thereafter, the patient was considered to have an indeterminate response (i.e. interpretation not applicable); if any serum showed neutralization activity, the patient was considered to have positive seroconversion. Patients with an indeterminate response were excluded from calculation of the seroconversion rate. This definition is based on the premise that no patients had previous exposure to MERS-CoV, as this was the first MERS outbreak in Korea as a non-endemic country.</p>
<p id="p0045">During the outbreak, MERS-CoV exposure dates and symptom onsets were clearly identified in most patients, owing to thorough contact investigation and monitoring of exposed individuals (
<xref rid="bb0015" ref-type="bibr">Cho et al., 2016</xref>
,
<xref rid="bb0090" ref-type="bibr">Park et al., 2016</xref>
). MERS-related symptoms included fever, myalgia, cough, sputum, and diarrhea. To provide a common point of reference, we used ‘days post onset of illness (
<italic>dpoi</italic>
)’ to evaluate MERS-CoV-infected patients. For asymptomatic patients, the day of diagnosis of MERS-CoV infection was considered as day of symptom onset (
<xref rid="bb0055" ref-type="bibr">Ko et al., 2016</xref>
).</p>
</sec>
<sec id="s0030">
<label>2.4</label>
<title>Serologic tests for MERS-CoV antibody</title>
<sec id="s0035">
<label>2.4.1</label>
<title>Enzyme-linked immunosorbent assay (ELISA) IgG and IgA</title>
<p id="p0050">Anti-MERS-CoV ELISA IgG and IgA (Euroimmun, Lübeck, Germany) were based on soluble MERS-CoV spike protein S1 domain expressed in HEK-293 T cells (
<xref rid="bb0075" ref-type="bibr">Muller et al., 2014</xref>
,
<xref rid="bb0080" ref-type="bibr">Muller et al., 2015</xref>
,
<xref rid="bb0085" ref-type="bibr">Muth et al., 2015</xref>
,
<xref rid="bb0105" ref-type="bibr">Raj et al., 2013</xref>
). Sera were tested according to the manufacturer's instructions with 1:100 dilutions. Secondary detection was done with peroxidase-labeled anti-human IgG and IgA. Cutoff values of OD ratio 0.4 for ELISA IgG and 0.2 for ELISA IgA were applied in the present study, as these values exhibited optimal performance in predicting neutralization activity (
<xref rid="bb9005" ref-type="bibr">Ko et al., 2017</xref>
).</p>
</sec>
<sec id="s0040">
<label>2.4.2</label>
<title>IFA IgM</title>
<p id="p0055">Anti-MERS-CoV IFA IgM (Euroimmun) was performed with slides carrying Vero cells infected with full MERS-CoV (
<xref rid="bb0040" ref-type="bibr">Corman et al., 2012b</xref>
,
<xref rid="bb0065" ref-type="bibr">Meyer et al., 2014</xref>
,
<xref rid="bb0075" ref-type="bibr">Muller et al., 2014</xref>
,
<xref rid="bb0080" ref-type="bibr">Muller et al., 2015</xref>
). Sera were tested according to the manufacturer's instructions with 1:10 dilutions. Weekly positive IFA intensity was considered cutoff intensity value of IFA IgM, which exhibited optimal performance in predicting neutralization activity (
<xref rid="bb9005" ref-type="bibr">Ko et al., 2017</xref>
).</p>
</sec>
<sec id="s0045">
<label>2.4.3</label>
<title>PRNT</title>
<p id="p0060">MERS-CoV PRNT was performed as previously described (
<xref rid="bb0065" ref-type="bibr">Meyer et al., 2014</xref>
,
<xref rid="bb0075" ref-type="bibr">Muller et al., 2014</xref>
,
<xref rid="bb0080" ref-type="bibr">Muller et al., 2015</xref>
). Pre-dilution before setting up the log2-dilution series was 1:10, defining 1:20 as the lowest possible significant titer for categorizing a sample as positive (
<xref rid="bb0065" ref-type="bibr">Meyer et al., 2014</xref>
).</p>
</sec>
</sec>
<sec id="s0050">
<label>2.5</label>
<title>Statistical analysis</title>
<p id="p0065">For comparison of clinical variables between groups, one-way analysis of variance (ANOVA) or Kruskal-Wallis test was used for continuous variables, and chi-square or Fisher's exact test was used for categorical variables. Six-week survival probability was calculated using the Kaplan–Meier method. The Cox proportional hazard model and log-rank test were used to examine the association of seroconversion status with the 6-week mortality of MERS patients having pneumonia. All
<italic>P</italic>
-values were 2-tailed, and those <0.05 were considered to be statistically significant. R-3.3.1 for Windows (RStudio, Boston, MA, USA) was used for all statistical analyses.</p>
</sec>
</sec>
<sec id="s0055">
<label>3</label>
<title>Results</title>
<sec id="s0060">
<label>3.1</label>
<title>Serologic response of MERS-CoV infection according to the disease severity</title>
<p id="p0070">Seroconversion status of 42 MERS-CoV-infected patients is summarized in
<xref rid="t0005" ref-type="table">Table 1</xref>
. None of the Group 0 patients showed seroconversion, and the seroconversion rate gradually increased with increasing disease severity (0.0%, 60.0%, 93.8%, and 100% in groups 0, 1, 2, and 3, respectively;
<italic>P</italic>
 = 0.001). Seroconversion was observed from 14 to 24
<italic>dpoi</italic>
(18
<italic>dpoi</italic>
in median), mostly during the third week of illness (88.0% of seroconverted patients with a known timeline). Group 3 patients showed slightly delayed timing of seroconversion compared to Group 2 patients (18.5 and 17.5
<italic>dpoi</italic>
in median, respectively, without statistical significance), and seroconversion during the fourth week of illness was exclusively observed in Group 3.
<table-wrap position="float" id="t0005">
<label>Table 1</label>
<caption>
<p>Seroconversion status of MERS-CoV-infected patients according to the disease severity group.</p>
</caption>
<alt-text id="al0015">Table 1</alt-text>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th rowspan="2">Variables</th>
<th colspan="4">Classification by the disease severity
<hr></hr>
</th>
</tr>
<tr>
<th>Group 0
<italic>Asymptomatic</italic>
(n = 3)</th>
<th>Group 1
<italic>Symptomatic</italic>
(n = 10)</th>
<th>Group 2
<italic>Pneumonia</italic>
(n = 18)</th>
<th>Group 3
<italic>Resp. failure</italic>
(n = 11)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative seroconversion</td>
<td>3 (100%)</td>
<td align="char">2 (20.0%)</td>
<td align="char">1 (5.6%)</td>
<td align="char">0 (0.0%)</td>
</tr>
<tr>
<td>Indeterminate response</td>
<td>0 (0.0%)</td>
<td align="char">5 (50.0%)</td>
<td align="char">2 (11.1%)</td>
<td align="char">2 (18.2%)</td>
</tr>
<tr>
<td>Positive seroconversion</td>
<td>0 (0.0%)</td>
<td align="char">3 (30.0%)</td>
<td align="char">15 (83.3%)</td>
<td align="char">9 (81.8%)</td>
</tr>
<tr>
<td> Timing unknown
<xref rid="tf0005" ref-type="table-fn">⁎</xref>
</td>
<td>N/A</td>
<td align="char">0/3 (0.0%)</td>
<td align="char">1/15 (6.7%)</td>
<td align="char">1/9 (11.1%)</td>
</tr>
<tr>
<td> Second week of illness</td>
<td>N/A</td>
<td align="char">0/3 (0.0%)</td>
<td align="char">1/14 (7.1%)
<xref rid="tf0010" ref-type="table-fn">†</xref>
</td>
<td align="char">0/8 (0.0%)</td>
</tr>
<tr>
<td> Third week of illness</td>
<td>N/A</td>
<td align="char">3/3 (100%)</td>
<td align="char">13/14 (92.9%)</td>
<td align="char">6/8 (75.0%)</td>
</tr>
<tr>
<td> Fourth week of illness</td>
<td>N/A</td>
<td align="char">0/3 (0.0%)</td>
<td align="char">0/14 (0.0%)</td>
<td align="char">2/8 (25.0%)</td>
</tr>
<tr>
<td> 
<italic>dpoi</italic>
</td>
<td>N/A</td>
<td align="char">17 (16–18)</td>
<td align="char">17.5 (14–20)</td>
<td align="char">18.5 (15–24)</td>
</tr>
<tr>
<td> 
<italic>dpex</italic>
</td>
<td>N/A</td>
<td align="char">22 (20–24)</td>
<td align="char">21.5 (19–30)</td>
<td align="char">24 (18–27)</td>
</tr>
<tr>
<td>Seroconversion rate
<xref rid="tf0015" ref-type="table-fn">‡</xref>
</td>
<td>0/0 (0.0%)</td>
<td align="char">3/5 (60.0%)</td>
<td align="char">15/16 (93.8%)</td>
<td align="char">9/9 (100%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="sp0045">
<p>Data are expressed as the number (%) of patients or median (range).</p>
</fn>
<fn id="sp0050">
<p>Seroconversion was confirmed by PRNT and a 1:20 dilution was defined as the lowest significant titer.</p>
</fn>
<fn id="sp0055">
<p>Abbreviations: MERS-CoV, Middle East respiratory syndrome coronavirus; Resp., respiratory;
<italic>dpoi</italic>
, days post onset of illness;
<italic>dpex</italic>
, days post exposure; IQR, interquartile range; PRNT, plaque reduction neutralization test.</p>
</fn>
</table-wrap-foot>
<table-wrap-foot>
<fn id="tf0005">
<label>⁎</label>
<p id="np0005">The timing of seroconversion was uncertain for 2 patients as the only sera available were collected after several months (
<italic>dpoi</italic>
79 and 140).</p>
</fn>
</table-wrap-foot>
<table-wrap-foot>
<fn id="tf0010">
<label>†</label>
<p id="np0010">At
<italic>dpoi</italic>
14.</p>
</fn>
</table-wrap-foot>
<table-wrap-foot>
<fn id="tf0015">
<label>‡</label>
<p id="np0015">Patients with an indeterminate response were excluded from seroconversion rate analysis.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</p>
<p id="p0075">Serologic responses of seroconverted patients are depicted according to the severity groups with 7-day intervals in
<xref rid="f0005" ref-type="fig">Fig. 1</xref>
. Serologic response occurred from the third week of illness, and antibody response is weaker in patients with mild symptomatic patients (Group 1) than patients with pneumonia (Groups 2 and 3). Group 2 patients showed robust increment of antibody titer during the third week (compared to the 2nd week, the median OD ratios of ELISA IgG and IgA increased more than 3-fold, and IFA IgM and PRNT increased from negative to 2+ and 1:80, respectively), and the titers did not significantly increase thereafter (in comparison of the median values of third week and fourth week, no statistical significance was observed). Meanwhile, Group 3 patients showed delayed and continuous increment of antibody titers from the third week: the median values of each serologic test were significantly higher during the fourth week compared to those of the third week in Group 3 (all
<italic>P</italic>
 < 0.05). In comparison between Groups 2 and 3, antibody titers of Group 3 patients during the third week were numerically lower than those of Group 2, although only ELISA IgG showed statistically significant difference (
<italic>P</italic>
 = 0.016). The antibody titers of Group 3 patients continuously increased, showing numerically higher titers compared to those of Group 2 patients during the fourth week (without statistical significance). Detailed serologic test results for each patient are presented according to timeline and severity groups in Supplementary Tables 2 to 5.
<fig id="f0005">
<label>Fig. 1</label>
<caption>
<p>Serologic responses of seroconverted MERS-CoV-infected patients, according to the severity groups with 7-day intervals.</p>
<p>The serologic responses of seroconverted MERS-CoV-infected patients are depicted according to the severity groups: symptomatic infection without pneumonia (Group 1), pneumonia without respiratory failure (Group 2), and pneumonia progressing to respiratory failure (Group 3). The mean values of each serologic test for 7-day intervals are presented in box-plots. The antibody titers of symptomatic patients rise after the 2nd week. Although PRNT titers were not statistically different between groups by the third week of illness, peak antibody response increased as severity increases.</p>
<p>(a) ELISA IgG in Group 1. (b) ELISA IgG in Group 2. (c) ELISA IgG in Group 3. (d) ELISA IgA in Group 1. (e) ELISA IgA in Group 2. (f) ELISA IgA in Group 3. (g) IFA IgM in Group 1. (h) IFA IgM in Group 2. (i) IFA IgM in Group 3. (j) PRNT in Group 1. (k) PRNT in Group 2. (l) PRNT in Group 3.</p>
<p>Abbreviations: MERS-CoV, Middle East respiratory syndrome coronavirus; ELISA, enzyme linked immunosorbent assay; OD, optical density; IFA, immunofluorescence assay; PRNT, plaque reduction neutralization test.</p>
</caption>
<alt-text id="al0005">Fig. 1</alt-text>
<graphic xlink:href="gr1_lrg"></graphic>
</fig>
</p>
</sec>
<sec id="s0065">
<label>3.2</label>
<title>Impaired Serologic Response of Fatal MERS Pneumonia</title>
<p id="p0080">As seroconversion rates were low in mild severity groups (0% in Group 0 and 60% in Group 1), outcome analysis was performed in patients having pneumonia (Groups 2 and 3). Only 25% of deceased patients showed seroconversion by the end of the third week of illness, while 100% of survived patients seroconverted (
<italic>P</italic>
 = 0.003,
<xref rid="t0010" ref-type="table">Table 2</xref>
). This difference also could be discriminated by ELISA IgG (with OD ratio cutoff value of 0.4,
<italic>P</italic>
 = 0.003) and ELISA IgA (with OD ratio cutoff value of 0.2,
<italic>P</italic>
 = 0.010). IFA IgM response was not significantly different between survivors and non-survivors (with intensity cutoff value of weakly positive,
<italic>P</italic>
 = 0.135). In a Kaplan–Meier analysis comparing seroconverted patients and non-converted patients by the third week of illness, seroconverted patients showed significantly higher survival probability compared to patients with negative seroconversion (
<xref rid="f0010" ref-type="fig">Fig. 2</xref>
,
<italic>P</italic>
 < 0.001 by log-rank test). Negative seroconversion in pneumonia patients by the third week of illness showed a hazard ratio of 27.83 (95% CI 2.76–280.21,
<italic>P</italic>
 = 0.005, by the Cox proportional hazard model) in predicting 6-week mortality.
<table-wrap position="float" id="t0010">
<label>Table 2</label>
<caption>
<p>Seroconversion rates by the end of third week of illness according to outcome of MERS-CoV-infected patients having pneumonia (Groups 2 and 3).</p>
</caption>
<alt-text id="al0020">Table 2</alt-text>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th>Serologic tests</th>
<th>Survived (n = 18)</th>
<th>Deceased (n = 4)</th>
<th>
<italic>P</italic>
value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRNT (≥ 1:20 dilution)</td>
<td align="char">18 (100%)</td>
<td align="char">1 (25%)</td>
<td align="char">0.003</td>
</tr>
<tr>
<td>ELISA IgG (OD ratio cutoff ≥0.4)</td>
<td align="char">18 (100%)</td>
<td align="char">1 (25%)</td>
<td align="char">0.003</td>
</tr>
<tr>
<td>ELISA IgA(OD ratio cutoff ≥0.2)</td>
<td align="char">17 (94.4%)</td>
<td align="char">1 (25%)</td>
<td align="char">0.010</td>
</tr>
<tr>
<td>IFA IgM (Intensity cutoff ≥ w+)</td>
<td align="char">16 (88.9%)</td>
<td align="char">2 (50%)</td>
<td align="char">0.135</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="sp0065">
<p>Data are expressed as the number (%) of patients. The population of this analysis is 22 MERS-CoV-infected patients with pneumonia (Groups 2 and 3) whose sera were collected during the third week of illness.</p>
</fn>
<fn id="sp0070">
<p>Abbreviation: MERS-CoV, Middle East respiratory syndrome coronavirus; PRNT, plaque reduction neutralization test; ELISA, enzyme-linked immunosorbent assay; OD, optical density; IFA, immunofluorescence assay; w+, weak positive.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="f0010">
<label>Fig. 2</label>
<caption>
<p>Survival probability of MERS-CoV-infected patients having pneumonia according to the seroconversion status by the third week of illness.</p>
<p>Survival probability according to the seroconversion status was evaluated in MERS-CoV-infected patients having pneumonia, whose seroconversion status during the third week of illness is identifiable. Seroconverted patients showed significantly higher survival probability compared to patients with negative seroconversion (
<italic>P</italic>
 < 0.001 by log-rank test). Seroconversion was confirmed by PRNT and a 1:20 dilution was defined as the lowest significant titer.</p>
<p>Abbreviations: MERS-CoV, Middle East respiratory syndrome coronavirus; PRNT, plaque reduction neutralization test.</p>
</caption>
<alt-text id="al0010">Fig. 2</alt-text>
<graphic xlink:href="gr2_lrg"></graphic>
</fig>
</p>
</sec>
</sec>
<sec id="s0070">
<label>4</label>
<title>Discussion</title>
<p id="p0085">Since previous hospital-associated outbreaks of MERS occurred in endemic countries, where primary infections flow from community into hospitals, detailed clinical data of each patient were hard to obtain (
<xref rid="bb0030" ref-type="bibr">Corman et al., 2016</xref>
). However, during the 2015 Korean MERS outbreak, the first outbreak in a non-endemic country, epidemiologic links and entire clinical course of each patients could be clearly identified (
<xref rid="bb0055" ref-type="bibr">Ko et al., 2016</xref>
,
<xref rid="bb0090" ref-type="bibr">Park et al., 2016</xref>
). Owing to the detailed epidemiologic and clinical information about patients, we could find out different serologic response depending on disease severity and outcome.</p>
<p id="p0090">Although different seroconversion rates depending on disease severity can be inferred from previous serologic investigation (
<xref rid="bb0070" ref-type="bibr">Min et al., 2016</xref>
), the number of evaluated MERS patients was limited to 14 and neutralization testing was not performed. In that study, a robust increment of ELISA IgG titer with a 3-fold increase in OD ratio was exclusively observed among patients with severe pneumonia, while mild infections exhibited a modest increment in OD ratio, if any. Likewise, we noted that asymptomatic MERS-CoV-infected cases did not show serologic response including PRNT within 6 months, and the seroconversion rate increased with the disease severity. Although the number of asymptomatic patients was limited to 3 in the present analysis, it is less likely that asymptomatic patients will experience seroconversion considering that even Group 1 patients with obvious MERS-related symptoms showed low seroconversion rate of 60%. This finding correlates with another serologic study that evaluated 11 rRT-PCR-confirmed MERS patients (
<xref rid="bb0020" ref-type="bibr">Choe et al., 2017</xref>
). In that study, antibody titers in 4 of 6 patients with mild illness were undetectable. In addition, most contact surveys of MERS-CoV could not detect additional rRT-PCR-negative PRNT-positive MERS-CoV infections (
<xref rid="bb0005" ref-type="bibr">Breakwell et al., 2015</xref>
,
<xref rid="bb0010" ref-type="bibr">Buchholz et al., 2013</xref>
,
<xref rid="bb0025" ref-type="bibr">Choi et al., 2016</xref>
,
<xref rid="bb0050" ref-type="bibr">Ko et al., 2017</xref>
). These findings imply that serologic surveys to detect subclinical infections among asymptomatic individuals would not be effective.</p>
<p id="p0095">Serologic response was delayed in Group 3 patients, and negative seroconversion by the third week of illness was associated with fatal outcome among patients with MERS pneumonia (HR 27.83, 95% CI 2.76–280.21,
<italic>P</italic>
 = 0.005). Delayed commencement of serologic response in severe disease was also suggested by previous report by Park et al. (
<xref rid="bb0095" ref-type="bibr">Park et al., 2015</xref>
). Although seroconversion timing was not statistically significantly delayed in Group 3 patients in the present study, delayed increment of IgG, IgA, and IgM titers after the third week was demonstrated in Group 3. However, the delayed serologic response in Group 3 could not be used as predictor for respiratory failure, as respiratory failure progressed during the 2nd week of illness (12
<italic>dpoi</italic>
in median).</p>
<p id="p0100">Meanwhile, negative seroconversion in MERS pneumonia by the third week of illness was associated with fatal outcome in the present analysis. Impaired serologic response in deceased patient was also noted in the paper of Corman et al., but insufficient clinical information, especially day of symptom onset, hampered more detailed analysis in association with timeline (
<xref rid="bb0030" ref-type="bibr">Corman et al., 2016</xref>
). In this study, we could obtain exact clinical information including day of symptom onset, and figured it out that seroconversion status by the third week of illness (by 21
<italic>dpoi</italic>
) can serve as a prognostic marker. Another important point is that MERS-CoV-infected patients in the present analysis died later than previous reports, probably owing to antiviral therapy or aggressive critical care including extracorporeal membrane oxygenation (ECMO). The median interval from symptom onset to death was 27 days in the present study, which is much longer than 11.5 days in previous reports (
<xref rid="bb0120" ref-type="bibr">Zumla et al., 2015</xref>
). Although rapidly deteriorating MERS cases would die before the third week of illness, there certainly is a population that benefit from prognosis prediction by serologic response. Aggressive managements including ECMO should be considered for pneumonia patients without seroconversion by the third week of illness. Although seroconversion status can be confirmed by neutralization tests, it cannot be readily performed worldwide (
<xref rid="bb0030" ref-type="bibr">Corman et al., 2016</xref>
). In the present analysis, seroconversion status of the third week assessed by ELISA IgG and IgA was similar with that by PRNT. These ELISA tests can be practically used for predicting poor prognosis of MERS pneumonia in the field of patient management.</p>
<p id="p0105">As a retrospective study, serum samples of each patient could not be collected with same interval. However, we applied strict criteria for seroconversion, excluding patients who did not have follow-up samples after the third week of illness as indeterminate response. In the previous report with the same patient population, we also suggest predictive factors for disease progression using clinical variables within 3 days from symptom onset (
<xref rid="bb0055" ref-type="bibr">Ko et al., 2016</xref>
). Together with the present paper, these factors could be used complementarily in managing MERS-CoV-infected patients. In addition, although we identified that seroconversion status by the third week was associated with fatal outcomes of MERS pneumonia, we could not perform multivariate analysis due to limited sample size. This finding need to be further evaluated with enough patient numbers of MERS pneumonia.</p>
</sec>
<sec id="s0075">
<label>5</label>
<title>Conclusions</title>
<p id="p0110">In conclusion, in a serologic investigation of 42 MERS-CoV-infected patients, mild cases showed low seroconversion rates, while fatal cases showed impaired serologic responses.</p>
</sec>
<sec id="s0080">
<title>Funding</title>
<p id="p0115">This work was supported by a Samsung Biomedical Research Institute (SBRI) grant [#SMX1161321]. CD reports funding by EU grants Antigone (GA no. 278976) and Prepare (GA no. 602525).</p>
</sec>
<sec id="s0085">
<title>Conflicts of Interest</title>
<p id="p0120">There are no potential conflicts of interest relevant to this article to report.</p>
</sec>
</body>
<back>
<ref-list id="bi0005">
<title>References</title>
<ref id="bb0005">
<element-citation publication-type="journal" id="rf0005">
<person-group person-group-type="author">
<name>
<surname>Breakwell</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pringle</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chea</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Richards</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Lack of transmission among close contacts of patient with case of Middle East respiratory syndrome imported into the United States, 2014</article-title>
<source>Emerg Infect Dis</source>
<volume>21</volume>
<year>2015</year>
<fpage>1128</fpage>
<lpage>1134</lpage>
<pub-id pub-id-type="pmid">26079176</pub-id>
</element-citation>
</ref>
<ref id="bb0010">
<element-citation publication-type="journal" id="rf0010">
<person-group person-group-type="author">
<name>
<surname>Buchholz</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Nitsche</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sanewski</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wevering</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Bauer-Balci</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October-November 2012</article-title>
<source>Euro Surveill</source>
<volume>18</volume>
<year>2013</year>
</element-citation>
</ref>
<ref id="bb0015">
<element-citation publication-type="journal" id="rf0015">
<person-group person-group-type="author">
<name>
<surname>Cho</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Ha</surname>
<given-names>Y.E.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>J.H.</given-names>
</name>
</person-group>
<article-title>MERS-CoV outbreak following a single patient exposure in an emergency room in South Korea: an epidemiological outbreak study</article-title>
<source>Lancet</source>
<volume>388</volume>
<year>2016</year>
<fpage>994</fpage>
<lpage>1001</lpage>
<pub-id pub-id-type="pmid">27402381</pub-id>
</element-citation>
</ref>
<ref id="bb0020">
<element-citation publication-type="journal" id="rf0020">
<person-group person-group-type="author">
<name>
<surname>Choe</surname>
<given-names>P.G.</given-names>
</name>
<name>
<surname>Perera</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>W.B.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>K.H.</given-names>
</name>
<name>
<surname>Bang</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>E.S.</given-names>
</name>
</person-group>
<article-title>MERS-CoV antibody responses 1 year after symptom onset, South Korea, 2015</article-title>
<source>Emerg Infect Dis</source>
<volume>23</volume>
<year>2017</year>
</element-citation>
</ref>
<ref id="bb0025">
<element-citation publication-type="journal" id="rf0025">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>W.S.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>C.I.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Joh</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>H.S.</given-names>
</name>
</person-group>
<article-title>Clinical presentation and outcomes of Middle East respiratory syndrome in the Republic of Korea</article-title>
<source>Infect Chemother</source>
<volume>48</volume>
<year>2016</year>
<fpage>118</fpage>
<lpage>126</lpage>
<pub-id pub-id-type="pmid">27433382</pub-id>
</element-citation>
</ref>
<ref id="bb0030">
<element-citation publication-type="journal" id="rf0030">
<person-group person-group-type="author">
<name>
<surname>Corman</surname>
<given-names>V.M.</given-names>
</name>
<name>
<surname>Albarrak</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Omrani</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Albarrak</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Farah</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Almasri</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection</article-title>
<source>Clin Infect Dis</source>
<volume>62</volume>
<year>2016</year>
<fpage>477</fpage>
<lpage>483</lpage>
<pub-id pub-id-type="pmid">26565003</pub-id>
</element-citation>
</ref>
<ref id="bb0035">
<element-citation publication-type="journal" id="rf0035">
<person-group person-group-type="author">
<name>
<surname>Corman</surname>
<given-names>V.M.</given-names>
</name>
<name>
<surname>Eckerle</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bleicker</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zaki</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Landt</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Eschbach-Bludau</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction</article-title>
<source>Euro Surveill</source>
<volume>17</volume>
<year>2012</year>
</element-citation>
</ref>
<ref id="bb0040">
<element-citation publication-type="journal" id="rf0040">
<person-group person-group-type="author">
<name>
<surname>Corman</surname>
<given-names>V.M.</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Costabel</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Timm</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Binger</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections</article-title>
<source>Euro Surveill</source>
<volume>17</volume>
<year>2012</year>
</element-citation>
</ref>
<ref id="bb0045">
<element-citation publication-type="journal" id="rf0045">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Choe</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>The characteristics of Middle Eastern respiratory syndrome coronavirus transmission dynamics in South Korea</article-title>
<source>Osong Public Health Res Perspect</source>
<volume>7</volume>
<year>2016</year>
<fpage>49</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="pmid">26981343</pub-id>
</element-citation>
</ref>
<ref id="bb0050">
<element-citation publication-type="journal" id="rf0050">
<person-group person-group-type="author">
<name>
<surname>Ko</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Baek</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Seok</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.Y.</given-names>
</name>
</person-group>
<article-title>Serologic evaluation of MERS screening strategy for healthcare personnel during a hospital-associated outbreak</article-title>
<source>Infect Control Hosp Epidemiol</source>
<volume>38</volume>
<year>2017</year>
<fpage>234</fpage>
<lpage>238</lpage>
<pub-id pub-id-type="pmid">27841103</pub-id>
</element-citation>
</ref>
<ref id="bb9005">
<element-citation publication-type="journal" id="rf9005">
<person-group person-group-type="author">
<name>
<surname>Ko</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Seok</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>S.Y.</given-names>
</name>
</person-group>
<article-title>Suggested new breakpoints of anti-MERS-CoV antibody ELISA titers: performance analysis of serologic tests</article-title>
<source>Suggested new breakpoints of anti-MERS-CoV antibody ELISA titers: performance analysis of serologic tests</source>
<year>2017</year>
<comment>[Epub ahead of print]</comment>
</element-citation>
</ref>
<ref id="bb0055">
<element-citation publication-type="journal" id="rf0055">
<person-group person-group-type="author">
<name>
<surname>Ko</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Ha</surname>
<given-names>Y.E.</given-names>
</name>
</person-group>
<article-title>Predictive factors for pneumonia development and progression to respiratory failure in MERS-CoV infected patients</article-title>
<source>J Infect</source>
<volume>73</volume>
<issue>5</issue>
<year>2016</year>
<fpage>468</fpage>
<lpage>475</lpage>
<pub-id pub-id-type="pmid">27519621</pub-id>
</element-citation>
</ref>
<ref id="bb0060">
<element-citation publication-type="journal" id="rf0060">
<person-group person-group-type="author">
<name>
<surname>Madani</surname>
<given-names>T.A.</given-names>
</name>
</person-group>
<article-title>Case definition and management of patients with MERS coronavirus in Saudi Arabia</article-title>
<source>Lancet Infect Dis</source>
<volume>14</volume>
<year>2014</year>
<fpage>911</fpage>
<lpage>913</lpage>
<pub-id pub-id-type="pmid">25253396</pub-id>
</element-citation>
</ref>
<ref id="bb0065">
<element-citation publication-type="journal" id="rf0065">
<person-group person-group-type="author">
<name>
<surname>Meyer</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Corman</surname>
<given-names>V.M.</given-names>
</name>
<name>
<surname>Reusken</surname>
<given-names>C.B.</given-names>
</name>
<name>
<surname>Ritz</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Godeke</surname>
<given-names>G.J.</given-names>
</name>
</person-group>
<article-title>Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013</article-title>
<source>Emerg Infect Dis</source>
<volume>20</volume>
<year>2014</year>
<fpage>552</fpage>
<lpage>559</lpage>
<pub-id pub-id-type="pmid">24655412</pub-id>
</element-citation>
</ref>
<ref id="bb0070">
<element-citation publication-type="journal" id="rf0070">
<person-group person-group-type="author">
<name>
<surname>Min</surname>
<given-names>C.K.</given-names>
</name>
<name>
<surname>Cheon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ha</surname>
<given-names>N.Y.</given-names>
</name>
<name>
<surname>Sohn</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Aigerim</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity</article-title>
<source>Sci Rep</source>
<volume>6</volume>
<year>2016</year>
<fpage>25359</fpage>
<pub-id pub-id-type="pmid">27146253</pub-id>
</element-citation>
</ref>
<ref id="bb0075">
<element-citation publication-type="journal" id="rf0075">
<person-group person-group-type="author">
<name>
<surname>Muller</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Corman</surname>
<given-names>V.M.</given-names>
</name>
<name>
<surname>Jores</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Younan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liljander</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>MERS coronavirus neutralizing antibodies in camels, eastern Africa, 1983-1997</article-title>
<source>Emerg Infect Dis</source>
<volume>20</volume>
<year>2014</year>
<fpage>2093</fpage>
<lpage>2095</lpage>
<pub-id pub-id-type="pmid">25425139</pub-id>
</element-citation>
</ref>
<ref id="bb0080">
<element-citation publication-type="journal" id="rf0080">
<person-group person-group-type="author">
<name>
<surname>Muller</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Corman</surname>
<given-names>V.M.</given-names>
</name>
<name>
<surname>Al-Masri</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Turkestani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ritz</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study</article-title>
<source>Lancet Infect Dis</source>
<volume>15</volume>
<year>2015</year>
<fpage>559</fpage>
<lpage>564</lpage>
<pub-id pub-id-type="pmid">25863564</pub-id>
</element-citation>
</ref>
<ref id="bb0085">
<element-citation publication-type="journal" id="rf0085">
<person-group person-group-type="author">
<name>
<surname>Muth</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Corman</surname>
<given-names>V.M.</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Assiri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Al-Masri</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Farah</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Infectious Middle East respiratory syndrome coronavirus excretion and serotype variability based on live virus isolates from patients in Saudi Arabia</article-title>
<source>J Clin Microbiol</source>
<volume>53</volume>
<year>2015</year>
<fpage>2951</fpage>
<lpage>2955</lpage>
<pub-id pub-id-type="pmid">26157150</pub-id>
</element-citation>
</ref>
<ref id="bb0090">
<element-citation publication-type="journal" id="rf0090">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Peck</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>S.Y.</given-names>
</name>
</person-group>
<article-title>Control of an outbreak of Middle East respiratory syndrome in a tertiary Hospital in Korea</article-title>
<source>Ann Intern Med</source>
<volume>165</volume>
<year>2016</year>
<fpage>87</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="pmid">27272273</pub-id>
</element-citation>
</ref>
<ref id="bb0095">
<element-citation publication-type="journal" id="rf0095">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>W.B.</given-names>
</name>
<name>
<surname>Perera</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Choe</surname>
<given-names>P.G.</given-names>
</name>
<name>
<surname>Lau</surname>
<given-names>E.H.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Chun</surname>
<given-names>J.Y.</given-names>
</name>
</person-group>
<article-title>Kinetics of serologic responses to MERS coronavirus infection in humans, South Korea</article-title>
<source>Emerg Infect Dis</source>
<volume>21</volume>
<year>2015</year>
<fpage>2186</fpage>
<lpage>2189</lpage>
<pub-id pub-id-type="pmid">26583829</pub-id>
</element-citation>
</ref>
<ref id="bb0100">
<element-citation publication-type="journal" id="rf0100">
<person-group person-group-type="author">
<name>
<surname>Payne</surname>
<given-names>D.C.</given-names>
</name>
<name>
<surname>Iblan</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Rha</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Alqasrawi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Haddadin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Al Nsour</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Persistence of antibodies against Middle East respiratory syndrome coronavirus</article-title>
<source>Emerg Infect Dis</source>
<volume>22</volume>
<year>2016</year>
<fpage>1824</fpage>
<lpage>1826</lpage>
<pub-id pub-id-type="pmid">27332149</pub-id>
</element-citation>
</ref>
<ref id="bb0105">
<element-citation publication-type="journal" id="rf0105">
<person-group person-group-type="author">
<name>
<surname>Raj</surname>
<given-names>V.S.</given-names>
</name>
<name>
<surname>Mou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Smits</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Dekkers</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Dijkman</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC</article-title>
<source>Nature</source>
<volume>495</volume>
<year>2013</year>
<fpage>251</fpage>
<lpage>254</lpage>
<pub-id pub-id-type="pmid">23486063</pub-id>
</element-citation>
</ref>
<ref id="bb0110">
<element-citation publication-type="other" id="rf0110">
<person-group person-group-type="author">
<name>
<surname>World Health Organization (WHO)</surname>
</name>
</person-group>
<article-title>WHO, Middle East respiratory syndrome coronavirus (MERS-CoV)</article-title>
<ext-link ext-link-type="uri" xlink:href="http://www.who.int/emergencies/mers-cov/en/" id="ir0010">http://www.who.int/emergencies/mers-cov/en/</ext-link>
<year>2017</year>
<comment>[accessed on March 14, 2017]</comment>
</element-citation>
</ref>
<ref id="bb0115">
<element-citation publication-type="journal" id="rf0115">
<person-group person-group-type="author">
<name>
<surname>Zaki</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>van Boheemen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bestebroer</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Osterhaus</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Fouchier</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia</article-title>
<source>N Engl J Med</source>
<volume>367</volume>
<year>2012</year>
<fpage>1814</fpage>
<lpage>1820</lpage>
<pub-id pub-id-type="pmid">23075143</pub-id>
</element-citation>
</ref>
<ref id="bb0120">
<element-citation publication-type="journal" id="rf0120">
<person-group person-group-type="author">
<name>
<surname>Zumla</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hui</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Perlman</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Middle East respiratory syndrome</article-title>
<source>Lancet</source>
<volume>386</volume>
<year>2015</year>
<fpage>995</fpage>
<lpage>1007</lpage>
<pub-id pub-id-type="pmid">26049252</pub-id>
</element-citation>
</ref>
</ref-list>
<sec id="s0090" sec-type="supplementary-material">
<label>Appendix A</label>
<title>Supplementary data</title>
<p id="p0130">
<supplementary-material content-type="local-data" id="ec0005">
<caption>
<p>Supplementary materials</p>
</caption>
<media xlink:href="mmc1.docx">
<alt-text>Image 1</alt-text>
</media>
</supplementary-material>
</p>
</sec>
<ack id="ac0005">
<title>Acknowledgements</title>
<p>We would like to express our sincerest condolences to the patients and families who suffered from the MERS outbreak. We also greatly appreciate the HCP and staff members at Samsung Medical Center and all other hospitals who worked together to overcome the MERS outbreak. Finally, we would like to thank Jinseob Kim for statistical advice and figure development, as well as Mingu Kang for IFA testing.</p>
</ack>
<fn-group>
<fn id="s0095" fn-type="supplementary-material">
<label>Appendix A</label>
<p id="p0135">Supplementary data to this article can be found online at
<ext-link ext-link-type="doi" xlink:href="10.1016/j.diagmicrobio.2017.07.006" id="ir0005">http://dx.doi.org/10.1016/j.diagmicrobio.2017.07.006</ext-link>
.</p>
</fn>
</fn-group>
</back>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Pmc/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C02 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000C02 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    Pmc
   |étape=   Corpus
   |type=    RBID
   |clé=     PMC:7127792
   |texte=   Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i   -Sk "pubmed:28821364" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1
Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021